Quick Answer
Arcturus Therapeutics Holdings Inc. reported R&D Expense of $112.21 million for fiscal year 2025.
Arcturus Therapeutics Holdings Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $112.21M | -42.5% |
| 2024 | $195.16M | +1.6% |
| 2023 | $192.13M | +30.0% |
| 2022 | $147.75M | -15.0% |
| 2021 | $173.76M | +200.4% |
| 2020 | $57.85M | +72.0% |
| 2019 | $33.64M | +98.1% |
| 2018 | $16.98M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $23.27M | -40.6% | -21.3% |
| June 30, 2025 | $29.58M | -49.6% | -15.2% |
| March 31, 2025 | $34.89M | -34.9% | -10.8% |
| September 30, 2024 | $39.13M | -23.4% | -33.3% |
| June 30, 2024 | $58.67M | +11.4% | +9.5% |
| March 31, 2024 | $53.57M | +3.5% | +4.9% |
| September 30, 2023 | $51.08M | +35.5% | -3.0% |
| June 30, 2023 | $52.67M | +37.9% | +1.7% |
- Arcturus Therapeutics Holdings Inc. showed a decrease of -42.5% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Arcturus Therapeutics Holdings Inc.’s r&d expense has grown by 560.8% (from $16.98 million to $112.21 million).
- The most recent figure is from Arcturus Therapeutics Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: